Atrial high-rate episodes are associated with more than twice the risk for mortality in patients with an implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator.
The emergence of new medicinal treatments may have changed the risk-benefit ratio of routine ICD implantation in patients with a severely abnormal LVEF after a heart attack.